DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Vulvovaginal Candidiasis - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Vulvovaginal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Vulvovaginal Candidiasis Overview
- Therapeutics Development
- Pipeline Products for Vulvovaginal Candidiasis - Overview
- Pipeline Products for Vulvovaginal Candidiasis - Comparative Analysis
- Vulvovaginal Candidiasis - Therapeutics under Development by Companies
- Vulvovaginal Candidiasis - Therapeutics under Investigation by Universities/Institutes
- Vulvovaginal Candidiasis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Vulvovaginal Candidiasis - Products under Development by Companies
- Vulvovaginal Candidiasis - Products under Investigation by Universities/Institutes
- Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development
- Cidara Therapeutics, Inc.
- Grupo Ferrer Internacional, S.A.
- NovaDigm Therapeutics, Inc.
- Scynexis, Inc.
- TGV-Laboratories
- Viamet Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/ss9pld/vulvovaginal
